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Rote of interteukin-6 in mediating mesangiat cell proliferation and
matrix production in vivo. Mesangial cell proliferation and matrix over-
production characterize many progressive glomerular diseases. Based on
currently available data, the role of intcrleukin-6 (IL-6) in mediating
mesangial cell proliferation and matrix production is controversial. The
present study attempts to clarity this issue by showing that: (1) IL-6 knock
out mice develop a normal glomerular architecture and in particular a
normal mesangium. (2) Mesangioproliferative glomerulonephritis in-
duced by Habu snake venom is equally severe in IL-6 knock out mice as
in control mice. (3) A continuous seven-day intraperitoneal infusion of 50
p.g recombinant human IL-6 into rats with a prior minimal (subnephrito-
genie) injury to mesangial cells does not induce glomerular cell activation,
cell proliferation, matrix production, leukocyte influx, platelet influx or
proteinuria. (4) A continuous seven-day IL-6 infusion into rats with
mesangioproliferative nephritis (anti-Thy 1.1 nephritis) increases matrix
protein transcription in the absence of detectable effects on matrix protein
accumulation and otherwise has no effect on the natural course of the
disease. We conclude from these findings that IL-6 is not an important
mediator of mesangial cell proliferation and matrix overproduction in
viva, and that currently little rationale exists to advocate anti-IL-6 therapy
in mesangioproliferative disease states.
Mesangial cell proliferation and mesangial matrix accumulation
are key features of various human glomerular diseases, including
IgA nephropathy, non-IgA mesangioproliferative glomerulone-
phritis, membranoproliferative glomerulonephritis, variants of
idiopathic focal sclerosis, lupus nephritis, and possibly diabetic
nephropathy [1, 2]. Mesangial cell proliferation and glomerular
matrix accumulation may also contribute to the development of
glomeruloscierosis independent of the underlying primary disease
[3, 41. Therefore, the study of factors that drive mesangial cell
proliferation and matrix production is important to understand
the pathogenesis and to design new therapeutic approaches for
mesangioproliferative glomerulonephritis and progressive gb-
merulosclerosis.
Interleukin-6 (IL-6) is produced in relatively large amounts by
mesangial cells in response to a variety of stimuli, such as
angiotensin II, lectins, matrix proteins, cytokines, and immune
complexes [5—11]. IL-6 has been reported to induce matrix protein
transcription and autocrine growth in mesangial cells in vitro
[12—14]. In vivo, gbomerular IL-6 overexpression was detected in
human glomerulonephritis types characterized by mesangial hy-
percellularity such as IgA nephropathy and some types of lupus
nephritis [15—19]. Furthermore, IL-6 transgenic mice developed a
mesangioproliferative glomerulonephritis [131 and the urinary
excretion of IL-6 has been correlated with mesangial hypercellu-
larity in patients with IgA nephropathy [13, 20, 21]. It has
therefore repeatedly been proposed that IL-6 is an important
mediator of mesangial cell proliferation and matrix overproduc-
tion [2, 8, 16, 22]. This theory has been challenged by several
observations. First, IL-6 transgenic mice develop a massive poly-
clonal B-cell activation, which in itself may be associated with
mesangioproliferative disease [23]. Second, the role of IL-6 in
mediating mesangial cell proliferation in vitro is controversial,
with follow-up studies showing either no effect [24, 25] or even
growth inhibition of mesangial cells treated with IL-6 [26]. Third,
increased urinary IL-6 excretion has been detected in a variety of
renal abnormalities and several patients with mesangial hypercel-
lularity failed to excrete detectable urinary IL-6 [21, 27].
In the present study we have attempted to further define the
role of IL-6 in the mediation of mesangial cell proliferation and
matrix production in vivo. Four experimental approaches were
chosen: (1) determine whether IL-6 knock out mice develop a
normal mesangium; (2) investigate whether experimental mesan-
gioproliferative gbomerulonephritis can be generated in IL-6
knock-out mice in a similar manner as in control mice; (3)
investigate the effects of an IL-6 infusion in rats with a prior
minimal (subnephritogenic) injury to the mesangial cells; (4)
investigate the effect of IL-6 infusion in rats with mesangioprolif-
erative nephritis (anti-Thy 1.1 nephritis).
Methods
Experimental design
All animal experiments were approved by the local review
boards.
Glomerular morphology in IL-6 knock-out mice
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Kidneys were obtained from 6 homozygous IL-6 knock-out
mice [28] (bred in the animal facilities of the Hannover Medical
School, 3 males, 3 females, age 58 to 60 days), 2 heterozygous IL-6
knock-out/wild-type mice (2 females, age 58 days) and 6 wild-type
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control mice (strain C57BL/6, obtained from the Zentralinstitut
für Versuchstierkunde, Hannover Medical School; 4 males, 2
females, age 54 days). Prior to sacrifice, a 24-hour urine collection
was performed and a serum sample was collected. The IL-6
genotype of each IL-6 knock-out mouse was verified by Southern
blot analysis.
Mesangioproliferative glomerulonephritis in IL-6 knock-out mice
Mesangioproliferative glomerulonephritis was induced in 6
homozygous IL-6 knock-out mice (3 males, 3 females, age 90
days) and 6 wild-type control mice (3 males, 3 females, age 85
days) by a single intravenous bolus injection of 4 mg/kg body wt
Habu snake venom (Trimeresurus fiavoviridis; Sigma, Deisen-
hofen, Germany). Following the injection, all mice were kept
under an infrared light for the next three hours to reduce
mortality. A 24-hour urine collection was performed from days 5
to 6 after disease induction. Mice were sacrificed at day 6 for the
histological examination of the kidneys.
IL-6 infusion in rats following injection of a subnephritogenic
anti- Thy 1.1 dose
Eleven male Wistar rats (Charles River) weighing about 180 g
received an intravenous bolus injection of 0.2 mg/kg monoclonal
anti-Thy 1.1 IgG1 (clone OX-7; European Collection of Animal
Cell Cultures, Salisbury, UK). Microosmotic pumps (filling vol-
ume 200 jl, delivery rate 1 pd/hr; Alzet Corporation, Palo Alto,
CA, USA) were then loaded with 50 sg recombinant human IL-6
(N = 5; kindly supplied by Dr. Amando Proudfood, Glaxo
Institute for Molecular Biology, Geneva, Switzerland) or phos-
phate buffered saline (PBS; N = 6). The pumps were implanted
into the peritoneal cavity at four hours after disease induction to
avoid any interference with glomerular anti-Thy 1.1 antibody
binding, which is maximal at one hour after injection [29]. One
hundred microliters of citrate-anticoagulated plasma samples
were collected at days 0, 2 and 7 after disease induction and 24
hour urine was collected from days 6 to day 7. Renal biopsies for
histological examination of the kidneys were obtained at days 2, 4
and 7 (sacrifice) after disease induction. Prior to the day 2 renal
biopsy, proliferating cells had been labeled with 5-bromo-2'-
deoxyuridine (BrdU; Sigma) by an intraperitoneal injection of 100
mg/kg body wt at 24, 32, and 40 hours after disease induction.
Following the renal biopsies at day 7, glomeruli were isolated
from the remaining pooled renal cortices of all rats per group by
differential sieving and glomerular RNA was prepared.
IL-6 infusion in rats with anti-Thy 1.1 mesangioproliferative
glomerulonephritis
Eleven male Wistar rats (Charles River) weighing about 180 g
received an intravenous bolus injection of 1 mg/kg monoclonal
anti-Thy 1.1 lgG1 (clone OX-7). Fourty-eight hours later, that is,
after the peak of mesangiolysis and at the start of the mesangio-
proliferative phase, a microosmotic pump (filling volume 200 jsl,
delivery rate 1 j.tl/hr) was implanted into the peritoneal cavity.
Pumps were loaded with 50 ig recombinant human IL-6 (N 5)
or PBS (N = 6). One hundred microliter plasma samples were
collected at days 2, 4 and 9 after disease induction and 24 hour
urine was collected from days 8 to 9. Renal biopsies for histolog-
ical evaluation were obtained at days 4, 6 and at sacrifice (day 9).
Prior to the day 6 renal biopsy, proliferating cells had been labeled
with BrdU by an intraperitoneal injection at 120, 128, and 136
hours after disease induction. At sacrifice (day 9) glomeruli were
isolated by differential sieving from the pooled renal cortices of all
rats per group and glomerular RNA was prepared.
Renal morphology
Tissue for light microscopy and immunoperoxidase staining was
fixed in methyl Carnoy's solution [30] and embedded in paraffin.
Four micrometer sections were stained with the periodic acid-
Schiff (PAS) reagent and counterstained with hematoxylin. In the
PAS stained sections the total number of cells per glornerular
cross section as well as the number of mitoses within the glomer-
ular tuft (extrapolated to mitoses per 100 glomerular cross
sections) was determined.
Immunoperoxidase staining
Four micrometer sections of methyl Carnoy's fixed biopsy tissue
were processed by a direct or indirect immunoperoxidase tech-
nique as previously described [30]. Primary antibodies included:
• 1A4, a murine monoclonal antibody to an NH2-terminal
synthetic decapeptide of a-smooth muscle actin (Dako, Glostrup,
Denmark) [31].
• D33, a murine monoclonal IgG1 antibody against human
muscle desmin (Dako) [32].
• PC 10 (Oncogene Science Inc., Uniondale, NY, USA), a
murine 1gM monoclonal antibody against human PCNA, which is
expressed by actively proliferating cells. We have previously
shown, in angiotensin II infused rats, that cell proliferation as
assessed by anti-PCNA antibody correlates with the cell prolifer-
ation as assessed by the conventional method of 3H-thymidine
incorporation [33].
• BU-1, a murine monoclonal antibody against bromo-de-
oxyuridine [341 containing nuclease in Tris buffered saline (Am-
ersham, Braunschweig, Germany).
• ED1 (Serotec, Oxford, UK), a murine monoclonal IgG
antibody to a cytoplasmic antigen present in monocytes, macro-
phages and dendritic cells [351.
• PL-l, a murine monoclonal antibody against rat platelets
[36].
• affinity purified polyclonal goat anti-human/bovine type IV
collagen (Southern Biotechnology Inc., Birmingham, AL, USA).
• an affinity purified IgG fraction of polyclonal rabbit anti-rat
fibronectin (Southern Biotechnology).
• a polyclonal, biotinylated horse anti-mouse IgG antibody
(Vector, Burlingame, CA, USA).
For all biopsies, negative controls consisted of substitution of
the primary antibody with equivalent concentrations of an irrele-
vant murine monoclonal antibody or normal rabbit or goat IgG.
Evaluation of all slides was performed by an observer, who was
unaware of the origin of the slides.
To obtain mean numbers of proliferating cells or infiltrating
leukocytes in glomeruli, more than 30 consecutive cross sections
of glomeruli containing more than 20 discrete capillary segments
were evaluated and mean values per kidney were calculated. To
obtain total counts of proliferating cells or infiltrating leukocytes
in the renal cortical tubulointerstitium over 40 grid fields (range
40 to 60), measuring 0.36 mm2 each, were analyzed and, again,
mean counts per kidney were obtained. For the evaluation of the
immunoperoxidase stains for a-smooth muscle actin, desmin, type
IV collagen, fibronectin and platelets, each glomerular area and
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Fig. 1. Light microscopic appearance of a typical glomerulus of an IL-6 knock-out mouse (A) and a wild-type mouse (B). No abnormal morphological
features are present (PAS stain; magnification x 1000). C and D show the electron microscopic appearance of glomerular segments of IL-6 knock-out
micc. (C) Glomerular segment with regular mcsangium, typical mesangial cells and no increase in mesangial matrix; the glomcrular basement membrane
and podocytes also exhibit a normal morphology. (D) Higher magnification of a mesangial cell with a typical nucleus and typical filaments at the plasma
membrane. Abbreviations are: M, mesangial cell; E, endothelium; EY, erythrocyte; P, podocyte. Light microscopic appearance of a glomerulus with a
mesangial nodule in an IL-6 knock-out mouse (E) or wild-type mouse (F) at six days after the injection of Habu snake venom. Nodule formation appears
similar in both mouse strains. (PAS stain; magnification x 1000).
tubulointerstitial grid field was graded semiquantitatively, and the
mean score per biopsy was calculated. Each score reflects mainly
changes in the extent rather than intensity of staining and
depended on the percentage of the glomerular tuft area or grid
field showing positive staining: 0 = absent staining or less than 5%
of the area stained; 1 5 to 25%; II = 25 to 50%; IH = 50 to 75%;
IV = >75%. We have recently described that this semiquantita-
tive scoring system is not only highly reproducible among different
observers, but that the data also are highly correlated with those
obtained by computerized morphometry [37].
Staining for glomerular mouse IgG, that is, anti-Thy 1.1 anti-
body, was graded as 0 (negative), I (trace), II (moderate) or III
(strong), and a mean glomerular score was calculated.
Electron microscopy
Renal tissue was cut into 1 mm slices and fixed for 24 hours in
a 2.5% glutaraldehyde solution. Tissue was then embedded in
araldite. Ultrathin sections were contrasted with lead citrate and
viewed in a transmission electron microscope (Zeiss EM900).
Preparation of glomerular RNA and Northern analysis
Glomeruli were isolated by differential sieving [381. All glomer-
ular isolates were checked microscopically and exhibited a purity
of greater than 98%. Total RNA was extracted from glomeruli
with guanidinium isothiocyanate and subsequent ultracentrifuga-
tion through caesium chloride using standard procedures [39, 401.
The RNA content of the samples obtained was determined by UV
spectrophotometry at 260 and 280 nm. Samples with an OD
260/280 nm ratio of < 1.8 were discarded. For Northern analysis
the RNA was denatured and 3 or 10 .rg/lane were electrophoresed
through a denaturing 1% agarose/formaldehyde gel [41]. Integrity
of the RNA was assessed by visualization of the 28S and 18S
rRNA bands. Separated RNA was then transferred onto a nylon
membrane (Hybond N°; Amersham, Braunschweig, Germany) by
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Fig. 1. Continued.
capillary blotting and cross linked using a UV-crosslinker (Strat-
agene, Heidelberg, Germany). Hybridization was performed using
digoxigenin labeled riboprobes which were generated using a
Digoxigenin RNA Labeling Kit (Boehringer, Mannheim, Ger-
many) and hybridized probe was detected using the Digoxigenin
Nucleic Acid Detection Kit (Boehringer) with minor modifica-
tions. Band intensities were scanned with a densitometer (Hero-
lab, Wiesloch, Germany) and corrected for the relative intensities
of the 28S rRNA signal as detected by hybridization with a 28S
rRNA eDNA probe.
The fibronectin and n1(IV) collagen probe were 420 bp and 296
bp, respectively, cDNAs which were generated from total rat
glomerular RNA by RT PCR. The sequence of the primers
were: 5 '-CGTGAATFCCAGGCACTGACTACAAGATC-3' (fi-
bronectin sense); 5 '-CGGTCACTCGAGCGATGACATAGAT-
GGTGTAC-3' (fibronectin antisense); 5 '-CGTGAA]ITCGT-
GCGG]ITTGTGAAGCACCG-3' (o1(IV) collagen sense); and
5 '-AGCTCACTCGAGCTTCflTGAACATCTCGcTT-3' (n1(IV)
collagen antisense).
For in vitro transcription, the PCR products were cloned into
pBluescipt (Stratagene).
The 28S rRNA eDNA (a gift of L. Iruela-Arispe and H. Sage)
[421 was labeled with digoxigenin by random priming using a
digoxigenin random priming kit (Boehringer Mannheim) accord-
ing to the manufacturer's instructions.
Monitoring of the IL-6 infusion
To examine whether the dosage regimen was appropriate, the
infused human recombinant IL-6 and the biological effects were
assessed by measuring plasma concentrations of a2-macroglobulin
(the major hepatic acute phase protein in rats) by immunoelec-
trophoresis as described [431. IL-6 concentrations were measured
in the plasma samples using a commercially available kit (R&D
Systems, Biermann, Bad Nauheim, Germany). Finally, all mi-
croosmotic pumps were explanted at the end of the infusion
period (day 7) and cut open to ensure that all IL-6 had been
delivered from the pumps.
Miscellaneous measurements
Urinary protein was measured using the Bio-Rad Protein Assay
(Bio-Rad Laboratories GmbH, Munchen, Germany) and bovine
serum albumin (Sigma Chemical Co., St. Louis, MO, USA) as a
standard. Creatinine and urea were measured in serum using an
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Table 1. Glomerular characteristics of non-manipulated, 54- to 60-day-
old homozygous or hetcrozygous IL-fl knock-out or wild-type mice
IL-6 IL-6
knock-out knock-out
mice mice Wild-type
(homozygous) (heterozygous) mice(N=6) (N=2) (N=6)
Number of nuclei per
glomerular 35 13 40/33 36 14
cross section
Glomerular a-smooth
muscle actin staining 0.20 0.03 0.20/0.15 0.18 0.04
score
Glomerular desmin
staining score 1.02 0.03 1.11/1.00 1.03 0.04
Data are mean SD or individual values (heterozygous mice).
autoanalyzer (Beckman Instruments GmbH, Munchen, Ger-
many).
Statistical analysis
All values are expressed as mean SD. Statistical significance
(defined asP < 0.05) was evaluated using the Mann-Whitney rank
sum test. Correlations were assessed using linear regression
analysis.
Results
IL-6 knock-out mice develop a normal mesangium
As shown in Figure 1 A and B, IL-6 knock-out mice displayed
a glomerular and mesangial architecture that did not differ from
that of wild-type mice. Total glomerular nucleus counts in ho-
mozygous and heterozygous IL-6 knock-out mice were not differ-
ent from those obtained in wild-type mice (Table 1). Similarly,
glomerular expression of a-smooth muscle actin, a marker of
activated mesangial cells [38], was equally absent in all three
groups, while desmin, which is constitutively expressed by mesan-
gial cells [38], was equally present in all three groups (Table 1). By
electron microscopy glomeruli showed a regularly developed
mesangium with a normal cell number. The glomerular basement
membrane was typically structured and covered by podocytes with
typical foot processes (Fig. 1 C, D). No significant proteinuria or
hematuria was present in homozygous or heterozygous IL-6
knock-out mice, and serum urea and creatinine values were within
the normal range in all mice (data not shown).
Mesangioprolifrrative glomerulonephritis similarly develops in IL-6
knock-out and wild-type mice
In pilot experiments 4 mg/kg Habu snake venom was identified
as the maximally tolerated dose, since at 5 mg/kg of the venom a
high mortality was observed. At the 4 mg/kg dose about 20% of
the glomeruli exhibited hypercellular areas in both IL-6 knock-out
and wild-type mice at day 6 after disease induction (Table 2). In
each group nodular mesangial lesions (Fig. 1 E, F) developed in 2
of 6 rats. The frequency of mesangial nodules did not differ
significantly between IL-6 knock-out and wild-type mice (Table
2). Furthermore, scoring of glomerular markers of mesangial cell
activation, namely the expression of desmin and the de novo
expression of a-smooth muscle actin, did not reveal significant
differences between the two groups (Table 2). Neither IL-6
Table 2. Characteristics of IL-6 knock-out or wild-type mice at 6 days
after the induction of Habu snake venom mesangioproliferative
glomeruloncphritis
IL-6 knock-out Wild-type
_________ ________
mice(N= 6) mice(N= 6) P
20.5 13.7% 22.2 21.0% NSHypercellular glomeruli
Glotneruli with mesangial nodule
formations
Glomerular a-smooth muscle
actin staining score
Glomerular dcsmin staining score
Proteinuria mg/24 h
NS is not significantly different.
Individual frequencies per animal are shown
knock-out nor wild-type mice developed significant proteinuria
(Table 2).
IL-6 infusion has no effects in rats with preceding minimal
mesangial injuly
In PBS infused rats the injection of a low dose of OX-7 anti-Thy
1.1 antibody led to mild glomerular de novo a-smooth muscle
actin expression, a minor increase in desmin expression, as well as
a low grade increase in the number of glomerular mitotic figures,
monocyte/macrophage influx and matrix protein accumulation,
while no significant platelet influx was observed (Fig. 2). Cell
proliferation as assessed by counting of glomerular mitoses was
correlated with the counts of PCNA-positive nuclei (r = 0.75, P <
0.001) as well as with counts of BrdU positive nuclei (r =0.56,P =
0.07). None of the aforementioned parameters was significantly
altered in IL-6 infused rats as compared to PBS infused rats (Fig.
2). Northern analysis of glomerular RNA showed no detectable
expression of fibronectin mRNA in both groups under our study
conditions (data not shown), while cr1(IV) collagen mRNA was
weakly expressed in both IL-6 and PBS infused rats (Fig. 3A).
Densitometry and correction for the expression of 28S rRNA
yielded an 1.4-fold (range 1.1- to 1.7-fold; N = 3) increase of
a1(IV) collagen mRNA in IL-6 infused rats as compared to PBS
infused rats. In neither group did significant proteinuria or
hematuria develop. Weight gain during the seven-day study
period was similar (PBS infused rats, 5 8 g; IL-6 infused rats,
7 8 g). IL-6 infusion also had no apparent influence on the
binding of anti-Thy 1.1 antibody in the mesangium since staining
for murine TgG was not significantly different from that observed
in PBS infused rats (Fig. 2).
No tubulointerstitial damage occurred in PBS and IL-6 infused
rats as judged by PAS-staining of the sections and by the absence
of interstitial a-smooth muscle actin and desmin expression,
normal PCNA counts, monocyte/macrophage counts and normal
staining for type IV collagen and fibronectin (data not shown).
Table 3 shows that the infused IL-6 was biologically active, since
at day 2 of the infusion period plasma concentrations of the acute
phase protein a2-macroglobulin were significantly elevated over
those observed in PBS infused rats. Comparable levels of plasma
a2-macroglobulin have been measured previously after a bolus
injection of 4 rg IL-6 or 0.25 ig lipopolysaccharide into normal
rats [43]. Similar to findings in nephrotoxic nephritis [43], the
induction of immune-mediated glomerular injury also induced to
some degree the acute phase response, since a2-macroglobulin
0;0;0;0;10;13% 0;0;0;0;2;45% NS
0.33 0.07 0.63 0.77 NS
1.44 0.27 1.65 0.70 NS
3.9 1.9 3.1 1.8 NS
concentrations increased with time in the plasma of PBS infused
rats (Table 3). Measurement of the IL-6 plasma concentrations
obtained during the infusion period confirmed that high circulat-
ing levels were achieved at day 2, and that they dropped rapidly
after the end of the infusion, that is, at day 7 (Table 3).
IL-6 infusion induces matrix protein transcription but has no other
effects in rats with mesangioproliferative glomerulonephritis
In PBS infused rats the injection of the regular dose of OX-7
anti-Thy 1.1 antibody led to marked glomerular de novo a-smooth
muscle actin expression, a marked increase in desmin expression,
as well as increased cell proliferation, monocyte/macrophage
influx, platelet influx and matrix protein accumulation (Fig. 4)
similar to previously described findings 30, 38, 44]. Again, none of
the aforementioned parameters was significantly altered in IL-6
infused rats as compared to PBS infused rats (Fig. 4). Cell
proliferation was also not significantly different between IL-6 and
PBS infused rats when assessed by PCNA staining or BrdU
incorporation (data not shown). Northern analysis of glomerular
RNA for the expression of fibronectin or a1(IV) collagen mRNA
showed an up-regulation of both RNA species in the IL-6 infused
rats as compared to PBS infused rats (Fig. 3B). Densitometry and
correction for the expression of 28S rRNA yielded 6.0-fold (range
2.2- to 11.2-fold; N = 3) increases of fibronectin mRNA in IL-6
infused rats as compared to PBS infused rats, and 2.0-fold (range
1.8- to 2.1-fold; N = 3) increases of a1(IV) collagen mRNA.
Proteinuria (54.2 34.4 mg/24 hr) but no hematuria was present
at day 8 in PBS infused rats and was not significantly different
from that observed in IL-6 infused rats (64.8 26.9 mg/24 hr).
Weight gain during the seven-day study period was not signifi-
cantly different (PBS infused rats, 5 33 g; IL-6 infused rats, 27
8 g). IL-6 infusion also had no apparent influence on the binding
or clearance of anti-Thy 1.1 antibody in the mesangium since
staining for murine IgG was not significantly different from that
observed in PBS infused rats (Fig. 4).
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Fig. 3. (A) Demonstration of a1(IV) collagen mRNA in total giomerular RNA isolated from rats with subnephritogenic mesangial injuFy and injhsed from
days 0 to 7 with either PBS or 50 pg recombinant human IL-6. (B) Demonstration of fibronectin and a1(IV) collagen mRNA in total glomerular RNA
isolated from rats with mesangioproliferative anti-Thy 1.1 nephritis infused from days 2 to 9 after disease induction with either PBS or 50 pg
recombinant human IL-6.
Table 3. Plasma concentrations of a2-macroglobulin and IL-6 in IL-6
or PBS infused rats with either subnephritogenic mesangial injury or
anti-Thy 1.1 mesangioproliferative glomerulonephritis
Plasma a2-macroglobulin
concentration p.g/ml
Plasma IL-6
concentration pg/mi
IL-6 PBSIL-6 PBS
infused infused infused infused
Subnephritogenic
anti-Thy 1.1 dose;
day after disease
induction
dayo 135±33 119±32 0±0 0±0
day 2 5123 1137 1374 699" 52 21 0 oa
day 7 1678 474 1142 368 5 2 0 0"
Nephritogenic anti-
Thy 1.1 dose; day
after disease
induction
day2 550±158 852±357 0±0 0±0
day 4 3634 1431 1573 407" 42 15 3 3"
day 9 3744 1835 2636 526 12 10 2 5
"P < 0.05 versus PBS infused rats
No tubulointerstitial damage occurred in PBS and IL-6 infused
nephritic rats as judged by PAS-staining of the sections and by the
absence of interstitial a-smooth muscle actin and desmin expres-
sion, normal PCNA counts, monocyte/macrophage counts and
normal staining for type IV collagen and fibronectin (data not
shown).
As in the experiments with subnephritogenic anti-Thy 1.1
antibody doses, Table 3 again confirms that the infused IL-6 was
biologically active in the nephritogenic rats and that high circu-
lating levels of IL-6 were achieved during the infusion period.
Discussion
Glomerular morphology in IL-6 knock-out mice
To evaluate the potential role of IL-6 in mediating mesangial
cell proliferation and matrix production, we first examined the
glomerular morphology of IL-6 knock-out mice. The rationale for
this approach is provided by observations that ontogenetic events
are frequently recapitulated during glomerular disease [45].
Therefore, mesangial maldevelopment in IL-6 knock-out mice
would point to an ontogenetically important role of IL-6 and
would imply that IL-6 may play a similarly important role in
glomerulonephritis. However, we could not detect any significant
difference in the mesangial morphology of IL-6 knock-out mice by
light and electron microscopy when compared to wild-type mice.
Furthermore, the immunostaining pattern in these mice for two
cytoskeletal proteins was normal, namely desmin, whose expres-
sion is restricted to normal mesangial cells, and a-smooth muscle
actin, which is only expressed by activated mesangial cells in vivo
[38]. It could be argued that these findings do not exclude an
important role of IL-6 in mesangial ontogenesis since other
growth factors might have compensated for the lack of IL-6.
However, it is noteable that in the case of another well established
mesangial cell mitogen, platelet-derived growth factor (PDGF),
both PDGF B-chain knock-out mice as well as PDGF J3-receptor
knock-out mice completely failed to develop a mesangium [46,
71.
Mesangioproliferative glomerulonephritis in IL-6 knock-out mice
To further define the role of IL-6 in regulating mesangial cell
behavior in vivo, we adapted the rat model of Habu snake
venom-induced mesangioproliferative nephritis to mice. Similar
to findings in rats [48], Habu snake venom induced a focal
glomerulonephritis in wild-type mice, with less than one third of
the glomeruli involved. Again, genetic IL-6 deficiency had no
effect on the manifestation of the Habu nephritis, suggesting that
IL-6 is not of central importance in mediating mesangial cell
proliferation and matrix accumulation in this murine model of
mesangioproliferative glomerulonephritis.
IL-6 infusion in rats following injection of a subnephritogenic
anti-Thy 1.1 dose
In normal rats, toxicity studies performed by others using very
high IL-6 doses (daily subcutaneous injections of up to 500 pg/kg
IL-6 PBS
for 30 days) have failed to induce any renal abnormalities in rats
or mice [49, 501. However, failure to detect a cytokine effect in
normal animals does not exclude a potential role in disease.
Hence, we have described that other mesangial cell growth
factors, including basic fibroblast growth factor (bFGF) and
PDGF also exhibited no or little proliferative activity in rat
glomeruli when infused into normal rats [51—53]. However, fol-
lowing minor (subnephritogenic) mesangial injury, similar to that
induced in the present study, the mesangial cells became suscep-
tible to the mitogenic action of bFGF and PDGF in vivo and
marked proliferation could be observed [51, 52]. This "priming"
of the mesangial cells by subnephritogenic injury likely involved
modulation of receptor expression and/or altered post-receptor
responses [52, 54].
The above observations led us to test the effects of TL-6 in rats
with prior minimal mesangial injury rather than in normal rats. As
opposed to bFGF and PDGF, under these circumstances IL-6 had
no detectable effect on glomerular cell activation (as assessed by
the expression of a-smooth muscle actin and desmin [38]), cell
proliferation or matrix accumulation. This was not due to biolog-
ical inactivity of the infused IL-6 since it led to a considerable
induction of the acute phase protein a2-macroglobulin, similar to
that observed in systemic inflammation induced by endotoxin
injection [431. However, we cannot exclude that higher, that is,
pharmacological, doses of IL-6 might have yielded different
biological responses under our experimental conditions.
JL-6 infusion in rats with anti- Thy 1.1 mesangioproliferative
glomerulonephritis
In a fourth experimental approach, we tested whether or not
the biological activity of IL-6 may depend on a synergism or
interactions with other cytokines, such as IL-I, PDGF, bFGF or
TGF-13, all of which are overexpressed in glomeruli of rats with
anti-Thy 1.1 nephritis and/or have been invoked in its pathogen-
esis [51, 55—57]. Again, IL-6 had no significant effect on a large
variety of damage parameters in rats with a fully established
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mesangioproliferative glomerulonephritis. The only detectable
effect of the IL-6 infusion, apart from augmenting the acute phase
protein synthesis, was an up-regulation of glomerular matrix
protein mRNA levels. These data corroborate previous in vitro
findings in which IL-6 stimulation of mesangial cells also led to
increased matrix protein transcription [141. The lack of a detect-
able parallel increase of matrix protein deposition in our study
may be due to either one of three possibilities: (a) relative
insensitivity of our semiquantitative immunostaining scores to
small increases in matrix protein deposition, (b) a post-transcrip-
tional block in the matrix protein synthesis or effects of IL-6 on
one of the various steps of matrix protein assembly, or (c) a
concomitant increase in proteolytic activity. Independent of this
latter issue, our data do not support a major role of IL-6 in
mediating glomerular extracellular matrix accumulation in vivo.
Similarly, in a murine model of mesangioproliferative IgA ne-
phropathy, IL-6 administration had no adverse effects on the
In conclusion, using four different experimental approaches, we
have failed to detect any evidence for a role of IL-6 in mediating
mesangial cell activation or growth in vivo. Despite an induction
of glomerular matrix protein transcription by IL-6 under special
circumstances, we also failed to establish IL-6 as an important
mediator of matrix protein accumulation. While each of the four
different approaches individually cannot provide definitive evi-
dence against a major role of IL-6 in modulating mesangial cell
behavior in vivo, the consistency of our findings in four very
diverse experimental situations strongly argues against an impor-
tant role of IL-6 in the pathogenesis of mesangioproliferative
diseases. This conclusion receives further support from recent
observations in a murine model of IgA nephropathy [58]. Taken
together, these experimental data at present do not support that
neutralization or antagonism of IL-6 should be a therapeutical
goal in mesangioproliferative glomerulonephritis.
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